ERBB2 and breast cancer: As the main finding, we can point out that the studies reporting a higher number of 18F-FDG-positive lesions included patients often affected by ductal carcinoma (i.e., 96%) [19] among which were also included those with ER+ HER2 + BC (11%) [19] and those with liver metastases (>10%) [12].